If you were carefully looking at both safety and efficacy data, this drug had many issues in both safety and efficacy data.
The drug showed safety problems after just a five day short course. In reality, some of those patients do require at least 7 day treatment One drug-related SAE and discountinuation due to hypertension indicated that the drug has serious systemic toxicity.
In terms of the efficacy, it is a very funny way to report the data like this. They should have shown clinical efficacy at Day 7 and 28 using clinical evaluable population (FDA recommended primary endpoint for this indication). In addition, we don't know what's % of clinical evaluation population. There were many discountinuations in middle and high dose groups. All of those patients have to be considered as failure.
The company has tried very hard to keep this program flow. It will be interesting to see how they are going to progress this program to Phase 3.
Investors should get out of this stock before too late.